CN
Search Within
P1750000
应用筛选条件
关键词:'P1750000'
显示 1-24 共 24 条结果 关于 "P1750000" 范围 论文
Meghana Mothi et al.
The Cochrane database of systematic reviews, 11(11), CD001949-CD001949 (2013-11-07)
Pimozide, formulated in the 1960s, continues to be marketed for the care of people with schizophrenia or related psychoses such as delusional disorder. It has been associated with cardiotoxicity and sudden unexplained death. Electrocardiogram monitoring is now required before and
Cynthia R Lorenzo et al.
American journal of clinical dermatology, 5(5), 339-349 (2004-11-24)
Pimozide is an antipsychotic drug of the diphenylbutylpiperidine class. In the US, it is FDA-approved only as a backup treatment for Gilles de la Tourette syndrome, although it has been used in other countries for many years as a treatment
C L Colvin et al.
Drug intelligence & clinical pharmacy, 19(6), 421-424 (1985-06-01)
The orphan drug pimozide was recently approved for marketing in the U.S. for the treatment of Tourette's syndrome (TS). TS is characterized by recurrent, involuntary motor movements and vocal tics, and is believed to be due to neurochemical dysfunction. Pimozide's
Hui Li et al.
Gene, 551(2), 279-289 (2014-09-10)
The signal transducer and activator of transcription 5a (Stat5a) modulates genes involved in proliferation and survival and plays pivotal roles in regulating the function of the mammary gland during pregnancy, lactation, and involution. However, there is little information about the
L Schafranek et al.
Leukemia, 29(1), 76-85 (2014-05-13)
Kinase inhibitors block proliferative signals in BCR-ABL1+ leukemic cells, but their capacity to induce apoptosis is poorly understood. Initial studies suggested that very brief exposure to kinase inhibitors was sufficient to induce apoptosis in chronic myeloid leukemia (CML) cells. However
Niraj S Trasi et al.
The journal of physical chemistry. B, 118(33), 9974-9982 (2014-07-31)
Amorphous forms of drugs are increasingly being used to deliver poorly water-soluble compounds. Therefore, understanding the magnitude and origin of differences in crystallization kinetics is highly important. The goal of this study was to better understand the factors that influence
A Sultana et al.
The Cochrane database of systematic reviews, (3)(3), CD001949-CD001949 (2000-07-25)
Pimozide was first formulated in the late 1960s and continues to be marketed for the care of those with schizophrenia or related psychoses such as delusional disorder. Pimozide is generally well tolerated apart from extrapyramidal side effects. It has, however
Dorothée Duluc et al.
Journal of immunology (Baltimore, Md. : 1950), 192(12), 5776-5788 (2014-05-20)
Recent compelling evidence indicates that Th17 confer host immunity against a variety of microbes, including extracellular and intracellular pathogens. Therefore, understanding mechanisms for the induction and activation of Ag-specific Th17 is important for the rational design of vaccines against pathogens.
Willem A van Vloten
Dermatology online journal, 9(2), 3-3 (2003-03-18)
Pimozide is widely used in psychiatry for chronic psychoses, schizophrenia, the syndrome of Gilles de la Tourette and to a certain extent, also in dermatology. The only dermatological indication is for delusions of parasitosis. Though there is a good rationale
Tamara Pringsheim et al.
The Cochrane database of systematic reviews, (2)(2), CD006996-CD006996 (2009-04-17)
Neuroleptic drugs with potent D-2 receptor blocking properties have been the traditional treatment for tics caused by Tourette Syndrome. Pimozide is the most studied of these. Use of these medications is declining because of concerns about side effects, and new
A Sultana et al.
The Cochrane database of systematic reviews, (2)(2), CD001949-CD001949 (2000-05-05)
Pimozide was first formulated in the late 1960s and marketed for the care of those with schizophrenia or related psychoses such as delusional disorder. To assess the effects of pimozide for people with schizophrenia, non-affective psychotic mental illness and delusional
L A Opler et al.
The Journal of clinical psychiatry, 52(5), 221-233 (1991-05-01)
Pimozide, a diphenylbutylpiperidine neuroleptic which is FDA-approved as a backup treatment for Gilles de la Tourette's syndrome, has been used abroad for many years as a treatment of schizophrenia and has been recently reported to be particularly effective in treating
C Sprissler et al.
Blood cancer journal, 4, e240-e240 (2014-08-26)
The spleen tyrosine kinase (SYK) was identified as an oncogenic driver in a broad spectrum of hematologic malignancies. The in vivo comparison of three SYK containing oncogenes, SYK(wt), TEL-SYK and IL-2-inducible T-cell kinase (ITK)-SYK revealed a general myeloexpansion and the
Felix J Hartmann et al.
Nature communications, 5, 5056-5056 (2014-10-04)
Genome-wide association studies implicate dysregulation of immune mechanisms in the pathogenesis of multiple sclerosis (MS). Particularly, polymorphisms in genes involved in T helper (TH) cell differentiation are associated with risk of developing MS. However, the underlying mechanism by which these
R M Pinder et al.
Drugs, 12(1), 1-40 (1976-01-01)
Pimozide 1-(1-[4,4-bis(4-fluorophenyl)butyl]-4-peperidinyl)-2-benzimidazolone, is the first of a new series of psychotropic drugs, the kiphenylbutylpiperidines. It is advocated for once-daily use as maintenance therapy in chronic schizophrenia and for the treatment of psychic and functional disorders induced by personality traits. Published
Pimozide.
Robert Smyj et al.
Profiles of drug substances, excipients, and related methodology, 37, 287-311 (2012-04-04)
Hawk Kim et al.
Annals of hematology, 94(5), 739-746 (2014-12-17)
The practical usefulness of Helicobacter pylori eradication for immune thrombocytopenia (ITP) patients is still controversial. However, some ITP patients respond to H. pylori eradication. We conducted a multi-center, open label, prospective phase II study to define the efficacy and toxicities
Qin Liang et al.
Nature chemical biology, 10(4), 298-304 (2014-02-18)
Protein ubiquitination and deubiquitination are central to the control of a large number of cellular pathways and signaling networks in eukaryotes. Although the essential roles of ubiquitination have been established in the eukaryotic DNA damage response, the deubiquitination process remains
M J Tueth et al.
Southern medical journal, 86(3), 344-349 (1993-03-01)
One of the more difficult psychopharmacologic aspects of current clinical psychiatry is finding a neuroleptic drug that adequately treats delusional states. Furthermore, many chronic schizophrenics remain resistant to standard antipsychotic medication, and clozapine is effective in only 30% to 50%
Cristina Sempio et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 970, 1-7 (2014-09-15)
The aim of the study was to develop and validate a simple, sensitive and specific method for the detection and quantitative determination of 88 substances among psychoactive drugs and their metabolites in whole blood, and to apply the procedure to
Anwar Anwar-Mohamed et al.
Toxicology letters, 230(3), 382-392 (2014-08-17)
Acquired cardiac long QT syndrome (LQTS) is a frequent drug-induced toxic event that is often caused through blocking of the human ether-á-go-go-related (hERG) K(+) ion channel. This has led to the removal of several major drugs post-approval and is a
J Rathbone et al.
The Cochrane database of systematic reviews, (3)(3), CD001949-CD001949 (2007-07-20)
Pimozide, formulated in the 1960s, continues to be marketed for the care of people with schizophrenia or related psychoses such as delusional disorder. It has been associated with cardiotoxicity and sudden unexplained deaths. Electrocardiogram monitoring is now required before and
Maria Stella Ritorto et al.
Nature communications, 5, 4763-4763 (2014-08-28)
Deubiquitylases (DUBs) are key regulators of the ubiquitin system which cleave ubiquitin moieties from proteins and polyubiquitin chains. Several DUBs have been implicated in various diseases and are attractive drug targets. We have developed a sensitive and fast assay to
Pimozide treatment of tic and Tourette disorders.
A K Shapiro et al.
Pediatrics, 79(6), 1032-1039 (1987-06-01)
1/1